Jose Pablo
Miramontes Gonzalez
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (18)
2022
-
Basal insulin analogues in people with diabetes and chronic kidney disease
Diabetic Medicine, Vol. 39, Núm. 2
2021
-
Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study
Atherosclerosis, Vol. 317, pp. 52-58
-
The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives
Applied Sciences (Switzerland), Vol. 11, Núm. 18
2020
-
In response to the paper ‘High-protein diet: A barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors?’
Diabetes, Obesity and Metabolism
-
Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry
Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834
-
Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
Kidney International
2019
-
Could renin-angiotensin-aldosterone system activation explain the amputations associated with canagliflozin? The nitric oxide hypothesis
Diabetes Research and Clinical Practice, Vol. 148, pp. 10-13
-
Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors
Revista Clinica Espanola, Vol. 219, Núm. 4, pp. 208-217
-
GLP-1 and the renin–angiotensin–aldosterone system
The Lancet Diabetes and Endocrinology
-
In response to Yaribeygi et al. "Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways"
Journal of Cellular Physiology
-
Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study
Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996
-
Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months
Diabetes Research and Clinical Practice, Vol. 158
-
VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia
Atherosclerosis, Vol. 285, pp. 17-22
2018
-
Reply to ‘Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes’ by Yoshimoto et al.
Journal of Investigative Medicine
-
Update concept of the dual blocking of the renin-angiotensin-aldosteron system. A new therapeutic option?
Medicina Clinica, Vol. 150, Núm. 1, pp. 33-38
-
Use of degludec insulin in chronic complex patients
European Journal of Internal Medicine
2017
-
Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)
Circulation, Vol. 135, Núm. 22, pp. 2133-2144
2016
-
Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up
Journal of the American College of Cardiology, Vol. 67, Núm. 11, pp. 1278-1285